Work

Abstract CT156: A Phase I study evaluating AC676, an innovative BTK chimeric degrader, in patients with relapsed and refractory B-cell malignancies

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2024-ct156

Authors: Jennifer Woyach, Michael Tees, Nancy Mota, Gladys Brown, Su Young Kim, Manish R. Patel

Institutions: The Ohio State University, Colorado Blood Cancer Institute

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4393989146

Cites:

Cited by: 3

Related to: 10